Evidence map›Paper›PMID 34680117›Full record

ArticleBiomolecules2021

Sex Hormone-Binding Globulin (SHBG) in Cerebrospinal Fluid Does Not Discriminate between the Main FTLD Pathological Subtypes but Correlates with Cognitive Decline in FTLD Tauopathies.

Marta Del Campo, Yolande A L Pijnenburg, Alice Chen-Plotkin, David J Irwin, Murray Grossman, Harry A M Twaalfhoven, William T Hu, Lieke H Meeter, John van Swieten, Lisa Vermunt and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Marta Del CampoNeurochemistry Laboratory, Department of Clinical Chemistry, and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0003-2808-3699
Yolande A L PijnenburgDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Amsterdam University Medical Centers, Location VUmc, 1081 HV Amsterdam, The Netherlands.
Alice Chen-PlotkinDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
David J IrwinDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Murray GrossmanDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Harry A M TwaalfhovenNeurochemistry Laboratory, Department of Clinical Chemistry, and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
William T HuDepartment of Neurology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Lieke H MeeterDepartment of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
John van SwietenDepartment of Neurology and Alzheimer Center, Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.
Lisa VermuntNeurochemistry Laboratory, Department of Clinical Chemistry, and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
Frans MartensEndocrine Laboratory, Amsterdam University Medical Centers, Location AMC, 1105 AZ Amsterdam, The Netherlands.
Annemieke C HeijboerEndocrine Laboratory, Amsterdam University Medical Centers, Location AMC, 1105 AZ Amsterdam, The Netherlands.ORCID 0000-0002-6712-9955
Charlotte E TeunissenNeurochemistry Laboratory, Department of Clinical Chemistry, and Biobank, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands.
Amsterdam Neuroscience · NLUniversity of Pennsylvania · USAmsterdam University Medical Centers · NLRutgers, The State University of New Jersey · USUniversidad San Pablo CEU · ES

Funding

Research Education ComponentP30AG072979 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DAVID A WOLK · 2021 to 2026
$24.8M
Understanding Environmental Contributions to Heterogeneity in bvFTD.P01AG066597 · NIA · UNIVERSITY OF PENNSYLVANIA · PI David John Irwin, Corey T McMillan · 2020 to 2026
$18.8M
TMEM106B in neurodegenerative diseaseR01NS082265 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI CHEN-PLOTKIN, ALICE S · 2013 to 2024
$4.7M
Biomarkers of cognitive decline in Parkinson's DiseaseR01NS115139 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI CHEN-PLOTKIN, ALICE S · 2019 to 2023
$3.6M
NIA NIH HHS P01 AG066597NIA NIH HHS P30 AG072979NIH HHS P01-AG066597NIH HHS P30-AG010124NINDS NIH HHS R01 NS082265NINDS NIH HHS R01 NS115139
6 · The paper itself

Abstract

Biomarkers to discriminate the main pathologies underlying frontotemporal lobar degeneration (FTLD-Tau, FTLD-TDP) are lacking. Our previous FTLD cerebrospinal fluid (CSF) proteome study revealed that sex hormone-binding globulin (SHBG) was specifically increased in FTLD-Tau patients. Here we investigated the potential of CSF SHBG as a novel biomarker discriminating the main FTLD pathological subtypes. SHBG was measured in CSF samples from patients with FTLD-Tau (

Indexed as

Cognitive DysfunctionFemaleFrontotemporal Lobar DegenerationHumansMaleMiddle AgedSex Hormone-Binding GlobulinTauopathiesSex Hormone-Binding GlobulinSHBG protein, humanbiomarkersCSFFTLD-TauFTLD-TDP

Identifiers

PMID34680117
PMCPMC8533538
OpenAlexW3202066480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.